Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor
NANJING,China,Sept. 2,2024--On September 02,2024,Simcere Zaiming,an innovative oncology company under Simcere Pharmaceutical Group (2096.HK),announced a collaboration agreement with Shenzhen TargetRx